Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT · References

References

CC BY 4.0 · NIHR Journals Library · approximately 16 min read

  1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112–17. 10.1016/S0140-6736(05)67889-016360788
  2. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer’s disease – friend or foe? Trends Neurosci 2009;32:619–28. 10.1016/j.tins.2009.07.00619796831
  3. Piau A, Nourhashémi F, Hein C, Caillaud C, Vellas B. Progress in the development of new drugs in Alzheimer’s disease. J Nutr Health Aging 2011;15:45–57. 10.1007/s12603-011-0012-x21267520
  4. Cummings J. Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin Transl Sci 2018;11:147–52. 10.1111/cts.1249128767185
  5. Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis 2018;64:S3–S22. 10.3233/JAD-17990129562511
  6. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, Aquino JP, Arbus C, Becq JP, et al. Prevention of progression to dementia in the elderly: rationale and proposal for a health-promoting memory consultation (an IANA Task Force). J Nutr Health Aging 2008;12:520–9. 10.1007/bf0298320418810298
  7. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001;322:1447–51. 10.1136/bmj.322.7300.144711408299
  8. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21:49–55. 10.1016/S0197-4580(00)00096-810794848
  9. Skoog I, Gustafson D. Update on hypertension and Alzheimer’s disease. Neurol Res 2006;28:605–11. 10.1179/016164106X13050616945211
  10. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60:1707–12. 10.1001/archneur.60.12.170714676044
  11. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 2011;26:699–708. 10.3233/JAD-2011-11034721709373
  12. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:b5465. 10.1136/bmj.b546520068258
  13. Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity. PLOS ONE 2018;13:e0206705. 10.1371/journal.pone.020670530383807
  14. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013;31:1073–82. 10.1097/HJH.0b013e3283603f5323552124
  15. Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012;69:1632–8. 10.1001/archneurol.2012.101022964777
  16. Hajjar I, Levey A. Association between angiotensin receptor blockers and longitudinal decline in tau in mild cognitive impairment. JAMA Neurol 2015;72:1069–70. 10.1001/jamaneurol.2015.100126368351
  17. Wharton W, Zhao L, Steenland K, Goldstein FC, Schneider JA, Barnes LL, et al. Neurofibrillary tangles and conversion to mild cognitive impairment with certain antihypertensives. J Alzheimers Dis 2019;70:153–61. 10.3233/JAD-19001131177216
  18. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC, Alzheimer’s Disease Neuroimaging Initiative. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun 2016;7:11934. 10.1038/ncomms1193427327500
  19. Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study [published online ahead of print July 23 2019]. Int J Epidemiol 2019. 10.1093/ije/dyz155
  20. Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer’s disease: progress toward disease prevention and treatment? J Alzheimers Dis 2018;62:1443–66. 10.3233/JAD-17111929562545
  21. Hanon O, Latour F, Seux ML, Lenoir H, Forette F, Rigaud AS, REAL.FR Group. Evolution of blood pressure in patients with Alzheimer’s disease: a one year survey of a French Cohort (REAL.FR). J Nutr Health Aging 2005;9:106–11. 10.1016/S0035-3787(05)85355-X15791354
  22. Hong KS, Kang DW, Bae HJ, Kim YK, Han MK, Park JM, et al. Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial. Acta Neurol Scand 2010;121:51–7. 10.1111/j.1600-0404.2009.01299.x19925528
  23. Zhao Z, Tuor UI, Barber P. Chronic treatment with losartan and cerebral ischemic tolerance. J Exp Stroke Transl Med 2009;2:32–40. 10.6030/1939-067X-2.2.32
  24. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 2010;67:1370–8. 10.1001/archneurol.2010.28421060014
  25. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci US 2000;97:9735–40. 10.1073/pnas.97.17.9735
  26. Buée L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM. Pathological alterations of the cerebral microvasculature in Alzheimer’s disease and related dementing disorders. Acta Neuropathol 1994;87:469–80. 10.1007/bf002941738059599
  27. Kalaria RN. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer’s disease. Neurobiol Aging 2009;30:1512–14. 10.1016/j.neurobiolaging.2007.10.02018187235
  28. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer’s disease. Brain Pathol 2008;18:240–52. 10.1111/j.1750-3639.2008.00132.x18363935
  29. Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, et al. Association of plasma Aβ peptides with blood pressure in the elderly. PLOS ONE 2011;6:e18536. 10.1371/journal.pone.001853621525986
  30. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1–40) and Abeta(1–42) and the risk of dementia: a prospective case–cohort study. Lancet Neurol 2006;5:655–60. 10.1016/S1474-4422(06)70501-416857570
  31. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, Kehoe PG. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2008;34:181–93. 10.1111/j.1365-2990.2007.00885.x17973905
  32. Miners JS, Baig S, Tayler H, Kehoe PG, Love S. Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 2009;68:902–14. 10.1097/NEN.0b013e3181afe47519606063
  33. Akatsu H, Ogawa N, Kanesaka T, Hori A, Yamamoto T, Matsukawa N, Michikawa M. Higher activity of peripheral blood angiotensin-converting enzyme is associated with later-onset of Alzheimer’s disease. J Neurol Sci 2011;300:67–73. 10.1016/j.jns.2010.09.03021040931
  34. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, et al. Large meta-analysis establishes the ACE insertion–deletion polymorphism as a marker of Alzheimer’s disease. Am J Epidemiol 2005;162:305–17. 10.1093/aje/kwi20216033878
  35. Kehoe PG, Wong S, Al Mulhim N, Palmer LE, Miners JS. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology. Alzheimers Res Ther 2016;8:50. 10.1186/s13195-016-0217-727884212
  36. Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT(1) receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011;36:857–70. 10.1038/npp.2010.22521150913
  37. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 2005;25:878–86. 10.1038/sj.jcbfm.960008215729290
  38. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Ironside JW, Naylor RJ, Williams TJ. Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res 1990;507:341–3. 10.1016/0006-8993(90)90294-L2337775
  39. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Ironside JW, Naylor RJ, Williams TJ. Angiotensin II inhibits cortical cholinergic function: implications for cognition. J Cardiovasc Pharmacol 1990;16:234–8. 10.1097/00005344-199008000-000091697379
  40. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003;9:275–308. 10.1111/j.1527-3458.2003.tb00254.x14530799
  41. Tian M, Zhu D, Xie W, Shi J. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett 2012;586:3737–45. 10.1016/j.febslet.2012.09.00422982863
  42. Zhu D, Shi J, Zhang Y, Wang B, Liu W, Chen Z, Tong Q. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLOS ONE 2011;6:e16037. 10.1371/journal.pone.001603721297982
  43. Kehoe PG, Hibbs E, Palmer LE, Miners JS. Angiotensin-III is increased in Alzheimer’s disease in association with amyloid-β and tau pathology. J Alzheimers Dis 2017;58:203–14. 10.3233/JAD-16126528387670
  44. Culman J, von Heyer C, Piepenburg B, Rascher W, Unger T. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol 1999;367:255–65. 10.1016/S0014-2999(98)00983-210079000
  45. DeKosky ST, Shih WJ, Schmitt FA, Coupal J, Kirkpatrick C. Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: correlation with cognitive severity. Alzheimer Dis Assoc Disord 1990;4:14–23. 10.1097/00002093-199040100-000022317335
  46. Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, et al. Tc-99m HMPAO SPECT in the evaluation of Alzheimer’s disease: correlation between neuropsychiatric evaluation and CBF images. J Neurol Neurosurg Psychiatry 1999;66:228–32. 10.1136/jnnp.66.2.22810071106
  47. Shiraishi H, Chang CC, Kanno H, Yamamoto I. The relationship between cerebral blood flow and cognitive function in patients with brain insult of various etiology. J Clin Neurosci 2004;11:138–41. 10.1016/j.jocn.2003.02.01314732371
  48. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010;13:195–201. 10.1089/rej.2009.094420370487
  49. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003;17:781–5. 10.1038/sj.jhh.100161314578918
  50. Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130–4. 10.1016/S0895-7061(99)00156-910604491
  51. Tedesco MA, Ratti G, Di Salvo G, Natale F. Does the angiotensin II receptor antagonist losartan improve cognitive function? Drugs Aging 2002;19:723–32. 10.2165/00002512-200219100-0000112390049
  52. McGuinness B, Todd S, Passmore AP, Bullock R. Systematic review: blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry 2008;79:4–5. 10.1136/jnnp.2007.11850518079296
  53. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al. Renin–angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011;10:43–53. 10.1016/S1474-4422(10)70250-720980201
  54. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhäger WH. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011;57:e6–7. 10.1161/HYPERTENSIONAHA.110.16514221189407
  55. van Middelaar T, van Vught LA, van Gool WA, Simons EMF, van den Born BH, Moll van Charante EP, Richard E. Blood pressure-lowering interventions to prevent dementia: a systematic review and meta-analysis. J Hypertens 2018;36:1780–7. 10.1097/HJH.000000000000182929927845
  56. Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, et al. Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. Neurology 2020;94:e267–e281. 10.1212/WNL.000000000000873231827004
  57. Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol 2020;19:61–70. 10.1016/S1474-4422(19)30393-X
  58. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer’s disease: current standing of the angiotensin hypothesis? J Alzheimers Dis 2012;30(Suppl. 2):S251–68. 10.3233/JAD-2012-111376
  59. Kehoe PG. Angiotensins and Alzheimer’s disease: a bench to bedside overview. Alzheimers Res Ther 2009;1:3. 10.1186/alzrt319674436
  60. Kehoe PG, Blair PS, Howden B, Thomas DL, Malone IB, Horwood J, et al. The Rationale and Design of the Reducing Pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) trial. J Alzheimers Dis 2018;61:803–14. 10.3233/JAD-17010129226862
  61. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O’Brien JT, Mountain G, et al. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol Assess 2017;21(26). 10.3310/hta21260
  62. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O’Brien JT, Mountain G, et al. Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: systematic review and consensus recommendations. PLOS ONE 2017;12:e0179521. 10.1371/journal.pone.017952128662127
  63. Hajjar I, Hart M, Milberg W, Novak V, Lipsitz L. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr 2009;9:48. 10.1186/1471-2318-9-4819922631
  64. Hajjar I, Hart M, Chen YL, Mack W, Novak V, C Chui H, Lipsitz L. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc 2013;61:194–201. 10.1111/jgs.1210023350899
  65. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, et al. Effect of Intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA 2019;321:553–61. 10.1001/jama.2018.2144230688979
  66. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA 2016;315:2673–82. 10.1001/jama.2016.705027195814
  67. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Naylor RJ. Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989;491:136–43. 10.1016/0006-8993(89)90095-42765877
  68. Miners JS, van Helmond Z, Raiker M, Love S, Kehoe PG. ACE variants and association with brain Aβ levels in Alzheimer’s disease. Am J Transl Res 2010;3:73–80.21139807
  69. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, et al. Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 2009;1:163–77.19956428
  70. Medvedev AE, Radko SP, Yurinskaya MM, Vinokurov MG, Buneeva OA, Kopylov AT, et al. Neurotoxic effects of Aβ6-42 peptides mimicking putative products formed by the angiotensin converting enzyme. J Alzheimers Dis 2018;66:263–70. 10.3233/JAD-18050030282362
  71. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008;375:446–9. 10.1016/j.bbrc.2008.08.03218715543
  72. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007;117:3393–402. 10.1172/JCI3154717965777
  73. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (Abeta(1–42)) to Abeta(1–40), and its inhibition enhances brain Abeta deposition. J Neurosci 2007;27:8628–35. 10.1523/JNEUROSCI.1549-07.200717687040
  74. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004;21:377–93. 10.2165/00002512-200421060-0000315084140
  75. Fox NC, Ridgway GR, Schott JM. Algorithms, atrophy and Alzheimer’s disease: cautionary tales for clinical trials. Neuroimage 2011;57:15–18. 10.1016/j.neuroimage.2011.01.07721296168
  76. Hua X, Gutman B, Boyle CP, Rajagopalan P, Leow AD, Yanovsky I, et al. Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. Neuroimage 2011;57:5–14. 10.1016/j.neuroimage.2011.01.07921320612
  77. Thompson WK, Holland D, Alzheimer’s Disease Neuroimaging Initiative. Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage 2011;57:1–4. 10.1016/j.neuroimage.2010.11.09221349340
  78. Clement C, Selman LE, Kehoe PG, Howden B, Lane JA, Horwood J. Challenges to and facilitators of recruitment to an Alzheimer’s disease clinical trial: a qualitative interview study. J Alzheimers Dis 2019;69:1067–75. 10.3233/JAD-19014631156168
  79. Kehoe PG, Turner N, Howden B, Jarutyte L, Clegg SL, Malone IB, et al. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer’s disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2021;20:895–906. 10.1016/S1474-4422(21)00263-534687634
  80. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44. 10.1212/wnl.34.7.9396610841
  81. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486–8. 10.1002/ana.4100705167396427
  82. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101. 10.1191/1478088706qp063oa
  83. Sandelowski M. Sample size in qualitative research. Res Nurs Health 1995;18:179–83. 10.1002/nur.47701802117899572
  84. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in ‘probable’ Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–72. 10.1136/jnnp.55.10.9671431963
  85. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010;6:67–77. 10.1038/nrneurol.2009.21520139996
  86. Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: longitudinal MRI study. Lancet 2003;362:1121–2. 10.1016/S0140-6736(03)14469-814550701
  87. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685–91. 10.1002/jmri.2104918302232
  88. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999;52:1687–9. 10.1212/wnl.52.8.168710331700
  89. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997;16:623–9. 10.1109/42.6407539368118
  90. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15–25. 10.1016/S0169-2607(97)01803-89113464
  91. Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091–108. 10.1016/j.neuroimage.2010.12.06721195780
  92. Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, et al. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer’s disease. Neuroimage 2010;51:1345–59. 10.1016/j.neuroimage.2010.03.01820230901
  93. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322–33. 10.1056/NEJMoa130483924450891
  94. Jorge Cardoso M, Leung K, Modat M, Keihaninejad S, Cash D, Barnes J, et al. STEPS: Similarity and truth estimation for propagated segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal 2013;17:671–84. 10.1016/j.media.2013.02.00623510558
  95. Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Weiner MW, et al. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage 2010;50:516–23. 10.1016/j.neuroimage.2009.12.05920034579
  96. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–64. 10.1176/ajp.141.11.13566496779
  97. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14. 10.1212/wnl.44.12.23087991117
  98. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98. 10.1016/0022-3956(75)90026-61202204
  99. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005;9(10). 10.3310/hta9100
  100. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996;25:113–20. 10.1093/ageing/25.2.1138670538
  101. Zekry D, Duyckaerts C, Moulias R, Belmin J, Geoffre C, Herrmann F, Hauw JJ. Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol 2002;103:481–7. 10.1007/s00401-001-0493-511935264
  102. Sudre CH, Cardoso MJ, Ourselin S, Alzheimer’s Disease Neuroimaging Initiative. Longitudinal segmentation of age-related white matter hyperintensities. Med Image Anal 2017;38:50–64. 10.1016/j.media.2017.02.00728282640
  103. Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J, Ourselin S. Bayesian model selection for pathological neuroimaging data applied to white matter lesion segmentation. IEEE Trans Med Imaging 2015;34:2079–102. 10.1109/TMI.2015.241907225850086
  104. Mutsaerts HJMM, Mirza SS, Petr J, Thomas DL, Cash DM, Bocchetta M, et al. Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain 2019;142:1108–20. 10.1093/brain/awz03930847466
  105. Elvsåshagen T, Mutsaerts HJ, Zak N, Norbom LB, Quraishi SH, Pedersen PØ, et al. Cerebral blood flow changes after a day of wake, sleep, and sleep deprivation. Neuroimage 2019;186:497–509. 10.1016/j.neuroimage.2018.11.03230471387
  106. Ibaraki M, Nakamura K, Toyoshima H, Takahashi K, Matsubara K, Umetsu A, et al. Spatial coefficient of variation in pseudo-continuous arterial spin labeling cerebral blood flow images as a hemodynamic measure for cerebrovascular steno-occlusive disease: a comparative 15O positron emission tomography study. J Cereb Blood Flow Metab 2019;39:173–81. 10.1177/0271678X1878166729869933
  107. Mutsaerts HJ, Petr J, Václavů L, van Dalen JW, Robertson AD, Caan MW, et al. The spatial coefficient of variation in arterial spin labeling cerebral blood flow images. J Cereb Blood Flow Metab 2017;37:3184–92. 10.1177/0271678X1668369028058975
  108. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC, Alzheimer’s Disease Neuroimaging Initiative investigators. Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 2010;31:1452–62, 1462.e1–2. 10.1016/j.neurobiolaging.2010.04.011
  109. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag 2008;4:269–86. 10.2147/TCRM.S145818728716
  110. Kanaide H, Ichiki T, Nishimura J, Hirano K. Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined. Circ Res 2003;93:1015–17. 10.1161/01.RES.0000105920.33926.6014645130
  111. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008;102:488–96. 10.1161/CIRCRESAHA.107.16280018096818
  112. Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, et al. Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial. PLOS Med 2018;15:e1002660. 10.1371/journal.pmed.100266030248105
  113. de Jong DLK, de Heus RAA, Rijpma A, Donders R, Olde Rikkert MGM, Günther M, et al. Effects of nilvadipine on cerebral blood flow in patients with Alzheimer disease. Hypertension 2019;74:413–20. 10.1161/HYPERTENSIONAHA.119.1289231203725
  114. Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs 2017;26:735–9. 10.1080/13543784.2017.1323868
  115. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008;7:683–9. 10.1016/S1474-4422(08)70143-118614402
  116. Howard R, Liu KY. Questions EMERGE as Biogen claims aducanumab turnaround. Nat Rev Neurol 2020;16:63–4. 10.1038/s41582-019-0295-931784690
  117. Schneider L. A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol 2020;19:111–12.31978357
← DiscussionAcknowledgements →

Attribution. Patrick G Kehoe; Nicholas Turner; Beth Howden; Lina Jarutyt; Shona L Clegg; Ian B Malone et al. (2021). Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2021. This work was produced by Kehoe et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK575022. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support